Live symbol workspace

ABBV market intelligence

Chart context, AI evidence, sentiment, related news, and verified outcome history are grouped into one asset dossier.

Current $208.84

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$198.40

Resistance

$219.28

Volume & Momentum

Volume

Weak

0.8x avg

Momentum

0%

Weak

Technical Context

Current price

$208.84

RSI context

50

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

30%

▼ 2.1 pts vs previous week

Avg confidence across 27 calls in the last 7 days

What sources say

Bullish 1 article

AbbVie (ABBV) Wins Health Canada Approval for Boey

Insider Trading

Refreshing insider trades from FinViz…

Technical Observations

Refreshing technical observations from FinViz...

ABBV News Intelligence (8 articles)

AI-curated news influencing ABBV price, sentiment, and trend

Explore All ABBV News with AI Analysis

Economy

1 week, 5 days ago

AbbVie (ABBV) Wins Health Canada Approval for Boey

AbbVie Inc. (NYSE:ABBV) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 23, 2026, …

Impact on ABBV: Potentially positive price action expected

Analysis of stock market developments showing bullish sentiment. Medium (60%)

View full analysis →

Yahoo Finance 60% confidence

Economy

1 month ago

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

Impact on ABBV: The article may have a mildly positive impact on AbbVie's stock price …

The article highlights AbbVie as a potentially underrated dividend growth stock in the S&P 500, … Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

1 month ago

AbbVie Delivers 400% Returns Beating The S&P 500 by 139%

Ten years ago, AbbVie (NYSE:ABBV) was a one-drug story. Humira, the world’s best-selling medicine, threw off the cash that funded …

Impact on ABBV: May pressure downward momentum

Financial market analysis indicating bearish sentiment based on current trends. High (70%)

View full analysis →

Yahoo Finance 70% confidence

Economy

1 month, 2 weeks ago

2 Reasons to Like ABBV and 1 to Stay Skeptical

Over the past six months, AbbVie’s shares (currently trading at $211.15) have posted a disappointing 9.8% loss, well below the …

Impact on ABBV: Neutral market sentiment indicated

Financial market analysis indicating neutral sentiment based on current trends. Medium (50%)

View full analysis →

Yahoo Finance 50% confidence

Economy

2 months, 1 week ago

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading session that saw all major indices …

Impact on ABBV: The unchanged interest rates may lead to a short-term boost in stock …

Wall Street analyst research calls for Thursday feature updates on several major stocks, including AbbVie, … Medium (60%)

View full analysis →

Yahoo Finance 60% confidence

Economy

2 months, 2 weeks ago

AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development

AbbVie Inc. (NYSE:ABBV) is one of the top S&P 500 stocks by index weight. On April 13, AbbVie Inc. (NYSE:ABBV) …

Impact on ABBV: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence